Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
Crossover investors—institutions that back both public and private companies—have been piling money into biotechs over the past few years. Today you can add Selecta Biosciences to the list of crossover-cash recipients,... Read more »
What summer doldrums? It’s still not even Labor Day, yet the deals are already coming fast and furious. So fire up the grill and read on for some Series A rounds,... Read more »
Companies are always looking to increase their odds of success, and Sage Therapeutics believes it’s come up with a clinical strategy to take some risk out of a risky business.
Sage... Read more »
There is no single race in gene therapy, or gene editing for that matter, more competitive than the one between companies trying to create treatments for hemophilia. And if one of... Read more »
Several years ago, Genzyme developed a drug called plerixafor (Mozobil) that’s used to help with bone marrow transplants. Now a group of folks that helped push that drug forward have reunited... Read more »
Former Genzyme CEO Henri Termeer has been active as an advisor and investor in the Boston biotech scene the past few years, forming ties with companies like Moderna Therapeutics, Lysosomal Therapeutics... Read more »
New drugs for fibrosis, an internal, often deadly type of scarring, have become the centerpiece of a number of biotech deals over the past few years. The latest just crossed the... Read more »
Just how far has Amicus Therapeutics come in two years? In 2013, the Cranbury, NJ-based company was reeling from a trial failure and restructuring to conserve cash. Now, it’s eyeing its... Read more »
If you tried to count on one hand the number of New York City biotech startups to get a substantial funding round this year, you’d probably have a few fingers left... Read more »
Nothing like a little drama to end your summer, right? Market volatility dragged biotech down this week, and then lifted it back up—at least as of Friday morning. But if you’re... Read more »
For all the hoopla that surrounds option-to-buy deals in biotech, the “buy” part is really just an option. Sometimes such deals lead to an acquisition, and sometimes they don’t. Case in... Read more »
If Syndax Pharmaceuticals’ latest financing is any indication, the Waltham, MA-based firm looks to have another shot at an initial public offering in mind.
Versant Ventures is about to launch its latest biotech incubator. And it’s picked the emerging New York life sciences scene as its home.
This morning, Versant, the San Francisco Bay Area... Read more »
[Corrected 8/24/15, 12:40 pm. See below.] The booming field of digital health means different things to different people. Even the president of StartUp Health, a New York-based firm... Read more »
The top story in biotech this week was the FDA’s approval of the first drug meant to boost women’s sex drive. The controversial flibanserin (Addyi) had been rejected in the... Read more »
Another week, another startup biotech that has amassed the type of investor group that can support an initial public offering. This time, it’s Boston-based WaVe Life Sciences.
WaVe, a startup trying... Read more »
Aveo Oncology was all but left for dead a few years ago after an FDA advisory panel panned its experimental cancer drug, tivozanib. But the Cambridge, MA-based company showed a little... Read more »
Investors in the broader biotech indices may have been losing money this week, but East Coast startups were finding it fairly easy to come by. A gene editing startup corralled $120... Read more »
November 17, 2015
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.